Abstract
Pancreatic cancer is one of the most lethal cancers and leading cause of cancer related death worldwide. Due to its nonspecific early symptoms, pancreatic cancer is difficult to diagnose before extensive local invasion and distant metastasis. The 5-year survival rate of patients diagnosed with pancreatic cancer is less than 5%. Their median survival time is less than 12 months. The molecular mechanisms of pancreatic tumor genesis are poorly understood. Mesothelin is a glycosylphosphatidylinositol (GPI) anchored cell surface protein, which has been found overexpressed in human pancreatic cancer. The function of mesothelin in tumor progression remains unclear. This review aims to outline the roles of mesothelin in pancreatic cancer cell proliferation, apoptosis and invasion, as well as its potential role in mesothelintargeted cancer therapy. Therefore, mesothelin is malignant factor for pancreatic cancer and could be exploited as an antigenic target of therapeutic cancer vaccine.
Keywords: Function, mesothelin, pancreatic cancer.
Graphical Abstract
Current Signal Transduction Therapy
Title:Clinical Significance of Mesothelin in Pancreatic Cancer
Volume: 11 Issue: 1
Author(s): Lei Zhang, Xiaoling Ni and Dayong Jin
Affiliation:
Keywords: Function, mesothelin, pancreatic cancer.
Abstract: Pancreatic cancer is one of the most lethal cancers and leading cause of cancer related death worldwide. Due to its nonspecific early symptoms, pancreatic cancer is difficult to diagnose before extensive local invasion and distant metastasis. The 5-year survival rate of patients diagnosed with pancreatic cancer is less than 5%. Their median survival time is less than 12 months. The molecular mechanisms of pancreatic tumor genesis are poorly understood. Mesothelin is a glycosylphosphatidylinositol (GPI) anchored cell surface protein, which has been found overexpressed in human pancreatic cancer. The function of mesothelin in tumor progression remains unclear. This review aims to outline the roles of mesothelin in pancreatic cancer cell proliferation, apoptosis and invasion, as well as its potential role in mesothelintargeted cancer therapy. Therefore, mesothelin is malignant factor for pancreatic cancer and could be exploited as an antigenic target of therapeutic cancer vaccine.
Export Options
About this article
Cite this article as:
Zhang Lei, Ni Xiaoling and Jin Dayong, Clinical Significance of Mesothelin in Pancreatic Cancer, Current Signal Transduction Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574362411666160210232918
DOI https://dx.doi.org/10.2174/1574362411666160210232918 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models?
Current Cancer Drug Targets Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression
Current Pharmaceutical Design Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review
Current Medicinal Chemistry Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets Impaired Expression and Function of Cancer-Related Enzymes by Anthocyans: An Update
Current Enzyme Inhibition The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Toxicity of Carbon Nanotubes
Current Drug Metabolism Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic
Current Gene Therapy Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Major Highlights of the CAR-TCR Summit, Boston, 2016
Anti-Cancer Agents in Medicinal Chemistry Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism